Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$133.70
-0.3%
$133.29
$99.71
$141.23
$233.90B0.736.16 million shs3.11 million shs
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$47.02
-1.3%
$47.73
$39.50
$63.33
$95.49B0.3612.88 million shs7.02 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$779.60
+0.0%
$773.61
$677.09
$972.53
$739.87B0.43.67 million shs1.45 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$69.05
-1.1%
$69.96
$57.00
$143.69
$308.84B0.647.26 million shs4.05 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.00%-0.52%+0.53%+7.42%+30.69%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.00%+1.45%-2.07%-15.01%+17.36%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+0.44%+1.67%+5.70%-13.20%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.00%+0.80%-4.39%+10.34%-50.36%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.7378 of 5 stars
2.43.04.24.52.92.51.3
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
4.9273 of 5 stars
3.23.04.24.03.43.31.3
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.9878 of 5 stars
4.44.03.34.03.01.71.9
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4.6349 of 5 stars
4.15.02.50.02.90.02.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.76
Moderate Buy$142.616.67% Upside
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.32
Hold$58.0023.36% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.75
Moderate Buy$1,011.6129.76% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.27
Hold$112.0062.20% Upside

Current Analyst Ratings Breakdown

Latest NVO, LLY, ABT, and BMY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/20/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$936.00
6/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
6/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$143.00
6/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
5/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/2/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$1,100.00 ➝ $1,050.00
5/1/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
5/1/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
5/1/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/28/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Reduce$1,150.00 ➝ $700.00
4/28/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Moderate Sell
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$41.95B5.54$6.55 per share20.42$27.62 per share4.84
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$48.30B1.98$5.90 per share7.97$8.08 per share5.82
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B16.40$14.22 per share54.84$15.03 per share51.87
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$42.12B7.32$3.89 per share17.73$4.66 per share14.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$13.40B$7.7117.3423.332.5531.89%19.01%10.82%7/17/2025 (Estimated)
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
-$8.95B$2.6717.617.721.3911.38%87.62%15.98%7/31/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$12.2963.4325.051.1422.67%85.51%15.74%8/7/2025 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$14.64B$3.3820.4314.821.3534.52%80.94%24.23%8/6/2025 (Estimated)

Latest NVO, LLY, ABT, and BMY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/31/2025Q2 2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.53N/AN/AN/A$11.32 billionN/A
7/17/2025Q2 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.25N/AN/AN/A$11.01 billionN/A
5/7/2025Q1 2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.92$0.92N/A$0.92N/A$11.87 billion
5/1/2025Q1 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$4.64$3.34-$1.30$3.06$12.77 billion$12.73 billion
4/24/2025Q1 2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.50$1.80+$0.30$1.21$10.77 billion$11.20 billion
4/16/2025Q1 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.07$1.09+$0.02$0.76$10.38 billion$10.36 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.361.77%N/A30.61%54 Years
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$2.485.27%N/A92.88%17 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.77%N/A48.82%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.642.38%N/A48.52%N/A

Latest NVO, LLY, ABT, and BMY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.78%8/15/20258/15/20259/10/2025
6/13/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.591.73%7/15/20257/15/20258/15/2025
6/17/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
quarterly$0.625.25%7/3/20257/3/20258/1/2025
5/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.73%5/16/20255/16/20256/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.26
1.78
1.27
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.65
1.28
1.17
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.18
1.37
1.06
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.70
0.74
0.56

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
76.41%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.09%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.73 billionOptionable
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
34,1002.04 billion2.03 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
47,000947.74 million946.50 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
77,3494.47 billion4.46 billionOptionable

Recent News About These Companies

2 International Dividend Stocks For Retirees
Brokerages Set Novo Nordisk A/S (NYSE:NVO) PT at $112.00
Are You Looking for a High-Growth Dividend Stock?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$133.70 -0.42 (-0.31%)
Closing price 07/3/2025 03:59 PM Eastern
Extended Trading
$133.70 +0.00 (+0.00%)
As of 07/3/2025 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Bristol Myers Squibb stock logo

Bristol Myers Squibb NYSE:BMY

$47.02 -0.62 (-1.29%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$47.02 0.00 (0.00%)
As of 07/3/2025 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$779.60 +0.32 (+0.04%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$778.00 -1.60 (-0.20%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$69.05 -0.77 (-1.10%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$69.12 +0.08 (+0.11%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.